GS
ACAD icon

GTS Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

GTS Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,712
Closed -$226K – 1244
2024
Q3 		$226K Sell
14,712
-12,153
-45% -$203K ﹤0.01% 3555
2024
Q2 		$437K Sell
26,865
-30,711
-53% -$496K 0.01% 2809
2024
Q1 		$1.06M Buy
57,576
+39,588
+220% +$981K 0.03% 1942
2023
Q4 		$563K Sell
17,988
-40,323
-69% -$963K 0.01% 2694
2023
Q3 		$1.22M Buy
+58,311
New +$1.58M 0.03% 1859

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return